Timber Pharmaceuticals Inc (AMEX: TMBR)’s stock price has dropped by -46.58 in relation to previous closing price of 2.34. Nevertheless, the company has seen a loss of -50.00% in its stock price over the last five trading days. Zacks Investment Research reported 2023-08-22 that Timber (TMBR) surges as LEO Pharma offers to acquire it for approximately $36 million.

Is It Worth Investing in Timber Pharmaceuticals Inc (AMEX: TMBR) Right Now?

and a 36-month beta value of 0.02. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”

The average price predicted for Timber Pharmaceuticals Inc (TMBR) by analysts is $3.03, which is $1.78 above the current market price. The public float for TMBR is 3.42M, and at present, short sellers hold a 0.28% of that float. On November 17, 2023, the average trading volume of TMBR was 361.22K shares.

TMBR’s Market Performance

TMBR stock saw a decrease of -50.00% in the past week, with a monthly decline of -55.36% and a quarterly a decrease of -11.97%. The volatility ratio for the week is 21.55%, and the volatility levels for the last 30 days are 9.68% for Timber Pharmaceuticals Inc (TMBR). The simple moving average for the past 20 days is -52.05% for TMBR’s stock, with a -42.63% simple moving average for the past 200 days.

TMBR Trading at -55.61% from the 50-Day Moving Average

After a stumble in the market that brought TMBR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.13% of loss for the given period.

Volatility was left at 9.68%, however, over the last 30 days, the volatility rate increased by 21.55%, as shares sank -55.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -59.02% lower at present.

During the last 5 trading sessions, TMBR fell by -50.00%, which changed the moving average for the period of 200-days by -47.92% in comparison to the 20-day moving average, which settled at $2.53. In addition, Timber Pharmaceuticals Inc saw -28.57% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for TMBR

Current profitability levels for the company are sitting at:

• -23125.86 for the present operating margin
• -293.07 for the gross margin

The net margin for Timber Pharmaceuticals Inc stands at -23299.05. The total capital return value is set at -164.83, while invested capital returns managed to touch -185.22. Equity return is now at value -3393.45, with -225.67 for asset returns.

Based on Timber Pharmaceuticals Inc (TMBR), the company’s capital structure generated 39.76 points at debt to equity in total, while total debt to capital is 28.45.

The liquidity ratio also appears to be rather interesting for investors as it stands at 1.95.

Conclusion

To sum up, Timber Pharmaceuticals Inc (TMBR) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.